Get the Stockscreener App
10.29
1.18%
0.12
After Hours:
10.29
Aura Biosciences Inc stock is traded at $10.29, with a volume of 88,923.
It is up +1.18% in the last 24 hours and up +18.00% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$10.17
Open:
$10.09
24h Volume:
88,923
Relative Volume:
0.57
Market Cap:
$508.46M
Revenue:
-
Net Income/Loss:
$-76.41M
P/E Ratio:
-5.145
EPS:
-2
Net Cash Flow:
$-64.56M
1W Performance:
-3.92%
1M Performance:
+18.00%
6M Performance:
+30.42%
1Y Performance:
-14.11%
1-Day Range:
$10.04
$10.39
1-Week Range:
$10.04
$10.73
52-Week Range:
$5.99
$12.38
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
Aura Biosciences Inc Stock (AURA) Latest News
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update - Defense World
One Aura Biosciences Insider Raised Stake By 232% In Previous Year - Yahoo Finance
Short Interest in Aura Biosciences, Inc. (NASDAQ:AURA) Decreases By 8.7% - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $98,808.00 in Stock - MarketBeat
Aura Biosciences VP sells shares worth $5,938 By Investing.com - Investing.com Australia
Aura Biosciences CEO Elisabet de los Pinos sells $98,787 in stock By Investing.com - Investing.com South Africa
Aura Biosciences CEO Elisabet de los Pinos sells $98,787 in stock - Investing.com
Aura Biosciences VP sells shares worth $5,938 - Investing.com
Don't Ignore The Insider Selling In Aura Biosciences - Simply Wall St
Aura Biosciences (NASDAQ:AURA) Stock Price Down 4.9% After Insider Selling - Defense World
Aura Biosciences CFO Julie Feder sells shares worth $302,361 - Investing.com India
Aura Biosciences (NASDAQ:AURA) Trading Down 4.9% on Insider Selling - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) CFO Sells $302,325.93 in Stock - MarketBeat
Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value - Seeking Alpha
Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Average Price Target from Analysts - Defense World
Long Term Trading Analysis for (AURA) - Stock Traders Daily
Aura Biosciences (NASDAQ:AURA) PT Raised to $22.00 at HC Wainwright - Defense World
Aura Biosciences stock hits 52-week high at $12.38 By Investing.com - Investing.com Australia
Aura Biosciences CEO sells $300,838 in stock By Investing.com - Investing.com Australia
Aura Biosciences reports promising early trial results - Investing.com India
Insider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells 24,992 Shares of Stock - MarketBeat
Aura Biosciences CEO sells $300,838 in stock - Investing.com
Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Aura Biosciences' Shares Touch 52-Week High on Positive Cancer Drug Data - MarketWatch
Aura Biosciences (NASDAQ:AURA) Hits New 12-Month High After Analyst Upgrade - MarketBeat
Aura Biosciences stock hits 52-week high at $12.38 - Investing.com
Aura Biosciences stock maintains Buy rating on promising trial results By Investing.com - Investing.com Canada
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease - Benzinga
Aura Biosciences (NASDAQ:AURA) Price Target Increased to $23.00 by Analysts at Scotiabank - MarketBeat
Aura Biosciences stock price target up 5%, H.C. Wainwright rates Buy after virtual oncology event - Investing.com Canada
Aura Biosciences Shares Surge After-Hour On Positive Clinical Trial Results - Stocks Telegraph
Multiple Clinical Complete Responses Demonstrated Following - GlobeNewswire
Aura Biosciences Reports Positive Phase 1 Trial Results - TipRanks
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial - The Manila Times
Aura Biosciences reports promising early trial results By Investing.com - Investing.com UK
Mark Plavsic Sells 7,383 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) Stock - MarketBeat
Aura Biosciences CTO Mark Plavsic sells $72,722 in shares By Investing.com - Investing.com South Africa
Aura Biosciences CTO Mark Plavsic sells $72,722 in shares - Investing.com India
With 58% ownership in Aura Biosciences, Inc. (NASDAQ:AURA), institutional investors have a lot riding on the business - Simply Wall St
3 Small-Cap Stocks Ready to Deliver Significant Growth - Benzinga
Short Interest in Aura Biosciences, Inc. (NASDAQ:AURA) Decreases By 12.2% - MarketBeat
(AURA) Proactive Strategies - Stock Traders Daily
Regency Capital Management Inc. DE Sells 97,744 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) is a favorite amongst institutional investors who own 58% - Yahoo Finance
Where are the Opportunities in (AURA) - Stock Traders Daily
Ensign Peak Advisors Inc Sells 105,316 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat
Aura Biosciences names interim CFO as Julie Feder departs By Investing.com - Investing.com Australia
Aura Biosciences names interim CFO as Julie Feder departs - Investing.com
Wall Street SWOT: Aura Biosciences stock shows promise amid cancer treatment trials - Investing.com
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):